Compass Therapeutics (CMPX) Income towards Parent Company (2018 - 2026)

Compass Therapeutics has disclosed Income towards Parent Company across 9 years of filings, most recently posting -$20.3 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at -$20.3 million, down 22.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$75.2 million (down 28.45% YoY), and the FY2025 annual result was -$72.8 million, down 28.63% from the prior year.
• Income towards Parent Company came in at -$20.3 million for Q1 2026 at Compass Therapeutics, down from -$18.0 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$7.2 million in Q1 2022 to a low of -$21.1 million in Q2 2025.
• The 5-year median for Income towards Parent Company is -$12.2 million (2024), against an average of -$13.3 million.
• Across the five-year window, Income towards Parent Company sank 100.42% in 2022 and grew 16.79% in 2023, its largest moves.
• Compass Therapeutics' Income towards Parent Company stood at -$11.6 million in 2022, then decreased by 15.71% to -$13.4 million in 2023, then declined by 23.55% to -$16.6 million in 2024, then declined by 8.54% to -$18.0 million in 2025, then declined by 12.83% to -$20.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$20.3 million (Q1 2026), -$18.0 million (Q4 2025), and -$15.8 million (Q3 2025), per Business Quant data.